MorphoSys's vision

MorphoSys is committed to develop exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

Events

20. Thu
June

J.P. Morgan European Healthcare Conference

London, UK
25. Tue
June

Meet the Team - Analyst and Investor Event

New York, NY, U.S.

Presentations

06/20/2018
JMP Securities Life Sciences Conference
06/06/2018
dbAccess Berlin
Berlin, Germany
05/21/2018
UBS Global Healthcare Conference
New York, US
05/03/2018
Q1 Call Presentation
03/13/2018
Year-End Results 2017
Planegg, Deutschland

Media and investors

Dr. Sarah Fakih

Head of Corporate Communications & Investor Relations

LinkedIn-Profile

Alexandra Goller

Director Corporate Communications & Investor Relations

LinkedIn-Profile

Dr. Julia Neugebauer

Director Corporate Communications & Investor Relations

LinkedIn-Profile

Dr.Verena Kupas

Manager Corporate Communications & Investor Relations

LinkedIn-Profile

Corporate Communications and Investor Relations
Phone: +49 89 89927 404
Fax: +49 89 89927 5404
Email Contact